Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance September 20, 2015 By CKD Digital
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance
SMT19969 has Good Activity Against Prevalent Clostridium difficile Ribotypes with Varying Antimicrobial Resistance September 20, 2015 By CKD Digital
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks